Objective: In 35 HCV infected patients with arthralgia and myalgia prevalence of anti-fodrin antibodies and anti-flilagrin antibodies was estimated--in comparison with other immunologic markers (ANA, krioglobulinemia, CCI, RF, anti-SSA) and clinical symptoms.
Results: Anti-filagrin antibodies were fund in one case. Anti-fodrin Ab--in two cases. Cryoglobulins, CCI, RF were frequent in estimated group. Many patients had different symptoms simultaneously. In 10 persons without serological markers clinical symptoms were the weakest.
Conclusions: In HCV infected patients arthralgias have different mechanism than in rheumatoid arthritis--although RF IgM is frequently found. Patients have often cryoglobulinemia and complexemia. Anti-SSA and anti-fodrin antibodies are rare in HCV-infected patients. Sicca syndrome in HCV infection is frequent, but etiology is probably different than in classic Sjögren's syndrome.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prevalence and clinical profile of hepatitis C virus infections in multitransfused thalassemic patients in the capital twin cities of Pakistan.
Braz J Biol
January 2025
Operational Research Center in Healthcare, Near East University, Mersin, Turkey.
Hepatitis C virus (HCV) presents a significant global health concern, affecting 3.3% of the world's population. The primary mode of HCV transmission is through blood and blood products.
View Article and Find Full Text PDFIntroducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda.
Clin Infect Dis
January 2025
Rwanda Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda.
Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. We describe a government sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) × 24 weeks retreatment program in Rwanda (November 2021-October 2022). Of 231 participants, 174 were cured (75.
View Article and Find Full Text PDFIdentification of near full-length human pegivirus type 2 (HPgV-2) genomes in blood donor samples co-infected with hepatitis C virus (HCV).
Microbiol Resour Announc
January 2025
Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Human pegivirus (HPgV) identified from an HCV-infected plasma sample through nanopore metagenomics. The analysis revealed a nearly complete HPgV-2 genome. Phylogenetic analysis confirmed its classification within the HPgV-2 genotype, providing insights into viral co-infection dynamics.
View Article and Find Full Text PDFSero-prevalence of hepatitis B and C and HIV among students at the Federal University of Health Sciences, Azare.
Niger Med J
January 2025
Department of Obstetrics and Gynaecology, Federal University of Health Sciences, Azare, Bauchi State, Nigeria.
Background: Infection with the human immunodeficiency virus and hepatitis viruses B and C have been reported to be endemic in some Nigeria's institutions of higher learning. Several studies have reported varying prevalence rates for hepatitis B and C viruses and HIV among undergraduate students in Nigerian universities.
Methodology: A cross-sectional descriptive prevalence study of hepatitis B and C viruses and HIV among students at Federal University of Health Sciences, Azare conducted on the 2nd of December 2023.
Hepatitis C Virus Seroprevalence, Incidence, and Screening Patterns in Ontario Preexposure Prophylaxis Users.
Open Forum Infect Dis
January 2025
Division of Infectious Diseases, St Michael's Hospital, Toronto, Canada.
Background: Hepatitis C virus (HCV) has emerged as a sexually transmitted infection in gay, bisexual, and other men who have sex with men (GBM). We estimated the seroprevalence and incidence of HCV infection and examined patterns of HCV testing among GBM using human immunodeficiency virus preexposure prophylaxis (PrEP) in Ontario, Canada.
Methods: We analyzed data from the Ontario PrEP Cohort Study (ON-PrEP), a prospective cohort of PrEP users from 10 Ontario clinics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!